Related Experiment Video
Updated: Feb 1, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study
Francesco Fortunato1, Adriana Saraceno1, Stefania Barone1
1Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
Abstract:
We aim to evaluate sleep disruption in people with multiple sclerosis (MS) compared to an age- and gender-matched control cohort using patient-reported outcome measures and formal polysomnography (PSG) scoring, and testing the effect of Nabiximols on these measures in people with MS. We enrolled adult individuals with MS who were eligible to receive nabiximols. Clinical variables and self-reported items like Pittsburgh Sleep Quality Index (PSQI) score were collected. Individuals underwent two full-night PSG recordings: baseline and after a 6-week nabiximols trial. Additionally, 24 healthy individuals (18 females; mean age:55.7 ± 9.5 years) were recruited as control cohort. Linear mixed-effects models (LMMs) using clinical and PSG parameters were used. Our cohort of 19 people with MS (16 females; mean age of 50.8 ± 10.2 years) with elevated PSQI (11.7 ± 2.8) exhibited: reduced sleep efficiency (SE)[P < 0.001,q-value = 0.003], reduced total sleep time (TST)[P = 0.0021,q-value = 0.005], higher number of awakenings [P < 0.001,q-value = 0.003], increased arousal-index (AI) [P < 0.001,q-value = 0.003], a greater periodic limb movement index (PLMI) [P < 0.001,q-value = 0.003] and a reduced proportion of REM [P < 0.001,q-value = 0.003] compared with the controls. The 6-weeks nabiximols trial resulted in a significant improvement in the PSQI [β 95%CI = -1.28 (-1.67, -0.88)] and in the following PSG measures: SE [β 95%CI = 1.57 (1.18, 1.95)], TST [β 95%CI = 0.93 (0.46, 1.40)], AI [β 95%CI = -1.41 (-1.79, -1.30)], PLMI [β 95%CI = -1.73 (-2.03, -1.43)] and REM sleep [β 95%CI = 1.44 (1.00, 1.87)]. Our prospective study reported a significant sleep disruption in MS and a great improvement in sleep parameters following a 6-week trial of Nabiximols, as indicated by LMMs using PSQI score and PSG measures. We suggest broadening the therapeutic indications of nabiximols to also include individuals with MS who experience significant sleep disruption.
Related Concept Videos
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Multiple Allele Traits
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
Understanding Sleep
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...
Sleep Apnea
The condition is more prevalent among...

